Search
Now showing items 1-5 of 5
Effect of Levosimendan in Patients with Severe Systolic Heart Failure and Worsening Renal Function
(ARQUIVOS BRASILEIROS CARDIOLOGIA, 2012)
Background: Levosimendan, a calcium sensitizer, increases the sensitivity of the heart to calcium, thus increasing myocardial contractility without a rise in intracellular calcium. It was recently shown that levosimendan ...
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens
(WILEY, 2016)
AimsTo assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fraction 35%). Methods and ...
Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
(AVES YAYINCILIK, 2010)
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosimendan does not increase cellular calcium intake, so that, does not cause intracellular calcium overload and related ...
Acute Effects of Levosimendan and Dobutamine on QRS Duration in Patients with Heart Failure
(ARQUIVOS BRASILEIROS CARDIOLOGIA, 2010)
Background: Levosimendan is a novel inotropic agent that enhances cardiac contractility without increasing cellular calcium intake, so that it is not supposed to cause intracellular calcium overload and related arrhythmias. ...
Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure
(OXFORD UNIV PRESS, 2013)
The aim of this study was to assess the prevalence of abnormal liver function tests (LFTs) and the associated clinical profile and outcome(s) in acute decompensated heart failure (ADHF) patients. Alteration in LFTs is a ...